FDA clears GE HealthCare's deep learning-based image processing software

The U.S. Food and Drug Administration (FDA) has cleared GE HealthCare's Precision DL deep learning-based image processing software.

The software is part of the company's Effortless Recon DL portfolio and is available for its Omni Legend PET/CT system.

Improvements for patient image processing the company touted for Precision DL include the following:

• 11% improvement on average in contrast recovery
• 23% improvement on average in contrast-to-noise ratio
• 42% increase on average in small, low contrast lesion detectability
• 14% improvement feature quantification accuracy